Portola Finally Gets FDA OK For Factor Xa Antidote AndexXa
It has taken a while and there were concerns that another trial may be needed before approval but AndexXa has got the green light in the US as a reversal agent for Eliquis and Xarelto. It comes with a warning and post-marketing commitments but Portola has very high hopes.
You may also be interested in...
The antiplatelet drug-reversal agent could see uptake grow in tandem with that of Brilinta, but there is a history of drugs in similar indications underperforming on the market.
The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.
Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla
The latest drug development news and highlights from our US FDA Performance Tracker.